TME-responsive nanoplatform for multimodal imaging-guided synergistic precision therapy of esophageal cancer via inhibiting HIF-1α signal pathway
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.10.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Guodong Ren und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Shanxi Medical University, Taiyuan 030001, PR China; Shanxi Province Brain Degenerative Diseases Precision Diagnosi…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Multimodal Imaging, Tumor Microenvironment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Shanxi Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Esophageal cancer (EC) is the sixth leading cause of cancer-related deaths, and its treatment poses significant challenges. In recent years, photodynamic, photothermal, and chemodynamic therapies have emerged as alternative strategies for tumor intervention. However, limitations such as poor tumor targeting, insufficient microenvironment responsiveness, and unclear mechanisms hinder their application. In this study, we found that hypoxia-inducible factor 1 alpha (HIF-1α) was highly expressed in clinical EC samples, which contributed to tumor malignancy and metastasis. We developed a carbon dots (CDs)-based tumor microenvironment (TME)-responsive nanoplatform, CDs-MnO2-Au-Cet (CMAC), designed for multimodal imaging-guided precision therapy in EC. Both in vitro and in vivo experiments demonstrated that CMAC effectively targeted and imaged EC cells and tissues. CMAC significantly inhibited tumor growth by inducing apoptosis and reducing lung metastasis. Mechanistically, CMAC administration led to a substantial downregulation of HIF-1α and its downstream targets, GLUT1 and MMP9. In summary, we presented a novel nanoplatform for imaging-guided synergistic therapy in EC, which demonstrated excellent anti-tumor growth and metastasis capabilities, along with favorable biocompatibility. This study laid the groundwork for developing innovative theranostic strategies for EC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Shanxi Medical University, Taiyuan 030001, PR China; Shanxi Province Brain Degenerative Diseases Precision Diagnosis and Treatment Engineering Research Center, Shanxi Medical University…
- School of Basic Medical Sciences, Shanxi Medical University, Taiyuan 030001, PR China.
Förderung
- Shanxi Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Ren, G., Wang, X., Yang, Z., Li, X., Ma, Y., Zhou, L., Yan, L., Ma, S., Li, L., Guo, L., Zhang, B., Diao, H., Wang, H., Wang, B., Lu, L., Zhang, C., & Liu, W. (2024). TME-responsive nanoplatform for multimodal imaging-guided synergistic precision therapy of esophageal cancer via inhibiting HIF-1α signal pathway. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.10.030
Vancouver
Ren G, Wang X, Yang Z, Li X, Ma Y, Zhou L, et al. TME-responsive nanoplatform for multimodal imaging-guided synergistic precision therapy of esophageal cancer via inhibiting HIF-1α signal pathway. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.10.030
BibTeX
@article{Ren2024,
author = {Ren, Guodong and Wang, Xuewei and Yang, Zhaobo and Li, Xiaowan and Ma, Yingyu and Zhou, Liang and Yan, Lili and Ma, Sufang and Li, Lihong and Guo, Lixia and Zhang, Boye and Diao, Haipeng and Wang, Haojiang and Wang, Bin and Lu, Li and Zhang, Chengwu and Liu, Wen},
title = {TME-responsive nanoplatform for multimodal imaging-guided synergistic precision therapy of esophageal cancer via inhibiting HIF-1α signal pathway},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.10.030}
}
EUVIMED